Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer

International Journal of Cancer

Volumn 135, Issue 9, 2014, Pages 2206-2214

  Micke, Patrick ^a   Mattsson, Johanna Sofia Margareta ^a   Edlund, Karolina ^a,b   Lohr, Miriam ^b   Jirström, Karin ^c   Berglund, Anders ^d   Botling, Johan ^a   Rahnenfuehrer, Jörg ^b   Marincevic, Millaray ^a   Pontén, Fredrik ^a   Ekman, Simon ^a   Hengstler, Jan ^b   Wöll, Stefan ^e   Sahin, Ugur ^f   Türeci, Özlem ^e  

^a UPPSALA UNIVERSITY   (Sweden)

^b TU DORTMUND UNIVERSITY   (Germany)

^c LUND UNIVERSITY   (Sweden)

^d Regional Cancer Center Uppsala Orebro   (Sweden)

^e Ganymed Pharmaceuticals AG   (Germany)

^f JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

claudin; gene expression profiling; non small cell lung cancer; targeted therapy; tissue microarray

Indexed keywords

CLAUDIN 18; CLAUDIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CANCER PROGNOSIS; CELL LINEAGE; CELL PROLIFERATION; CORRELATION ANALYSIS; EPITHELIUM CELL; GENETIC TRANSCRIPTION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLUS CELL; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY;

CLAUDIN; GENE EXPRESSION PROFILING; NON-SMALL-CELL LUNG CANCER; TARGETED THERAPY; TISSUE MICROARRAY;

ADENOCARCINOMA; AGED; BRONCHI; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CLAUDINS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROTEIN ISOFORMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84906278734     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28857     Document Type: Article

References (45)

1. Paccez JD, Vogelsang M, Parker MI, et al. The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications. Int J Cancer 2014; 134: 1024-33.
2. Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012; 150: 1107-20.
3. Janku F, Garrido-Laguna I, Petruzelka LB, et al. Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol 2011; 6: 1601-12.
4. Gautschi O, Zander T, Keller FA, et al. A patient with lung adenocarcinoma and RET fusion treated with vandetanib. J Thorac Oncol 2013; 8: e43-4.
5. Larsen JE, Cascone T, Gerber DE, et al. Targeted therapies for lung cancer: clinical experience and novel agents. Cancer J 2011; 17: 512-27.
6. Ohashi K, Maruvka YE, Michor F, et al. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol 2013; 31: 1070-80.
7. Schuler MH, Zvirbule Z, Lordick F, et al. Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas. ASCO Meeting Abstracts 2013; 31: 4080.
8. Soini Y,. Claudins in lung diseases. Respir Res 2011; 12: 70.
9. Gunzel D, Fromm M,. Claudins and other tight junction proteins. Comp Physiol 2012; 2: 1819-52.
10. Gupta IR, Ryan AK,. Claudins: unlocking the code to tight junction function during embryogenesis and in disease. Clin Genet 2010; 77: 314-25.
11. Sahin U, Koslowski M, Dhaene K, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res 2008; 14: 7624-34.
12. Hewitt KJ, Agarwal R, Morin PJ,. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 2006; 6: 186.
13. Runkle EA, Mu D,. Tight junction proteins: from barrier to tumorigenesis. Cancer Lett 2013; 337: 41-8.
14. Ding L, Lu Z, Lu Q, Chen YH,. The claudin family of proteins in human malignancy: a clinical perspective. Cancer Manag Res 2013; 5: 367-75.
15. Soini Y,. Tight junctions in lung cancer and lung metastasis: a review. Int J Clin Exp Pathol 2012; 5: 126-36.
16. Merikallio H, Paakko P, Harju T, et al. Claudins 10 and 18 are predominantly expressed in lung adenocarcinomas and in tumors of nonsmokers. Int J Clin Exp Pathol 2011; 4: 667-73.
17. Overgaard CE, Mitchell LA, Koval M,. Roles for claudins in alveolar epithelial barrier function. Ann N Y Acad Sci 2012; 1257: 167-74.
18. LaFemina MJ, Rokkam D, Chandrasena A, et al. Keratinocyte growth factor enhances barrier function without altering claudin expression in primary alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 2010; 299: L724-34.
19. Koval M,. Claudin heterogeneity and control of lung tight junctions. Ann Review Physiol 2013; 75: 551-67.
20. Tureci O, Koslowski M, Helftenbein G, et al. Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene 2011; 481: 83-92.
21. Sentani K, Oue N, Tashiro T, et al. Immunohistochemical staining of Reg IV and claudin-18 is useful in the diagnosis of gastrointestinal signet ring cell carcinoma. Am J Surg Pathol 2008; 32: 1182-9.
22. Karanjawala ZE, Illei PB, Ashfaq R, et al. New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8. Am J Surg Pathol 2008; 32: 188-96.
23. Tanaka M, Shibahara J, Fukushima N, et al. Claudin-18 is an early-stage marker of pancreatic carcinogenesis. J Histochem Cytochem 2011; 59: 942-52.
24. Soini Y, Takasawa A, Eskelinen M, et al. Expression of claudins 7 and 18 in pancreatic ductal adenocarcinoma: association with features of differentiation. J Clin Pathol 2012; 65: 431-6.
25. Shinozaki A, Shibahara J, Noda N, et al. Claudin-18 in biliary neoplasms. Its significance in the classification of intrahepatic cholangiocarcinoma. Virchows Archiv 2011; 459: 73-80.
26. Niimi T, Nagashima K, Ward JM, et al. claudin-18, a novel downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing. Mol Cell Biol 2001; 21: 7380-90.
27. Woll S, Schlitter AM, Dhaene K, et al. Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. Int J Cancer 2014; 134: 731-9.
28. Turksen K, Troy TC,. Claudin-6: a novel tight junction molecule is developmentally regulated in mouse embryonic epithelium. Dev Dyn 2001; 222: 292-300.
29. Ushiku T, Shinozaki-Ushiku A, Maeda D, et al. Distinct expression pattern of claudin-6, a primitive phenotypic tight junction molecule, in germ cell tumours and visceral carcinomas. Histopathology 2012; 61: 1043-56.
30. Rendon-Huerta E, Teresa F, Teresa GM, et al. Distribution and expression pattern of claudins 6, 7, and 9 in diffuse- and intestinal-type gastric adenocarcinomas. J Gastrointestinal Cancer 2010; 41: 52-9.
31. Zavala-Zendejas VE, Torres-Martinez AC, Salas-Morales B, et al. Claudin-6, 7, or 9 overexpression in the human gastric adenocarcinoma cell line AGS increases its invasiveness, migration, and proliferation rate. Cancer Invest 2011; 29: 1-11.
32. Ben-David U, Nudel N, Benvenisty N,. Immunologic and chemical targeting of the tight-junction protein Claudin-6 eliminates tumorigenic human pluripotent stem cells. Nature Commun 2013; 4: 1992.
33. Micke P, Edlund K, Holmberg L, et al. Gene copy number aberrations are associated with survival in histologic subgroups of non-small cell lung cancer. J Thorac Oncol 2011; 6: 1833-40.
34. Botling J, Edlund K, Lohr M, et al. Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin Cancer Res 2013; 19: 194-204.
35. Edlund K, Lindskog C, Saito A, et al. CD99 is a novel prognostic stromal marker in non-small cell lung cancer. Int J Cancer 2012; 131: 2264-73.
36. Mattsson JS, Imgenberg-Kreuz J, Edlund K, et al. Consistent mutation status within histologically heterogeneous lung cancer lesions. Histopathology 2012; 61: 744-8.
37. Lohr M, Edlund K, Botling J, et al. The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. Cancer Lett 2013; 333: 222-8.
38. Thornton M, Aslam MA, Tweedle EM, et al. The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer. Int J Cancer 2013; 133: 1408-18.
39. Tibshirani R, Hastie T,. Outlier sums for differential gene expression analysis. Biostatistics 2007; 8: 2-8.
40. Krause G, Winkler L, Mueller SL, et al. Structure and function of claudins. Biochim Biophys Acta 2008; 1778: 631-45.
41. Mineta K, Yamamoto Y, Yamazaki Y, et al. Predicted expansion of the claudin multigene family. FEBS Lett 2011; 585: 606-12.
42. Jung JH, Jung CK, Choi HJ, et al. Diagnostic utility of expression of claudins in non-small cell lung cancer: different expression profiles in squamous cell carcinomas and adenocarcinomas. Pathol Res Pract 2009; 205: 409-16.
43. Moldvay J, Jackel M, Paska C, et al. Distinct claudin expression profile in histologic subtypes of lung cancer. Lung Cancer 2007; 57: 159-67.
44. Matsuda M, Sentani K, Noguchi T, et al. Immunohistochemical analysis of colorectal cancer with gastric phenotype: claudin-18 is associated with poor prognosis. Pathol Int 2010; 60: 673-80.
45. Doebele RC, Camidge DR,. Targeting ALK, ROS1, and BRAF kinases. J Thorac Oncol 2012; 7: S375-6.